ElectroCore's non-invasive vagus nerve stimulation device, gammaCore, will be launched across Germany by Desitin for the treatment of migraine and cluster headache. The agreement with Desitin took effect on January 1, 2016. GammaCore is well known in Germany as many of the headache centres across the country took part in the successful clinical trial program.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.3 USD | +0.32% |
|
-0.91% | +5.85% |
01/07 | ElectroCore, Inc.(NasdaqCM:ECOR) added to Russell 3000E Index | CI |
01/07 | ElectroCore, Inc.(NasdaqCM:ECOR) added to Russell Microcap Index | CI |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+5.85% | 4.06Cr | |
+75.69% | 1.26TCr | |
-21.78% | 762.7Cr | |
-6.25% | 584.37Cr | |
+8.16% | 515.91Cr | |
-17.81% | 475.39Cr | |
+16.22% | 415.9Cr | |
-12.24% | 416.9Cr | |
-10.69% | 337.09Cr | |
-2.35% | 198.85Cr |
- Stock Market
- Equities
- ECOR Stock
- News electroCore, Inc.
- ElectroCore Appoints Desitin to Launch gammaCore for the Treatment of Primary Headache across Germany